No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Insiders At Arcellx Sold US$5.5m In Stock, Alluding To Potential Weakness
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating